Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response
Status:
Completed
Trial end date:
2020-08-28
Target enrollment:
Participant gender:
Summary
This will be a randomized, double-blind, placebo-controlled study. The study will use a
three-period, six-sequence, complete-block, cross-over study design to characterize two doses
of inhaled TD-8236 compared to placebo in subjects with mild asthma and a known response to
an allergen. Each of the three periods will be 14 days, followed by a washout period before
the next period.